

# Index

- ABCD scoring systems, 235–236, 237, 240–242
- abdominal aortic aneurysms, TIA and stroke, 27
- absolute risk reduction (ARR), 213, 218
- carotid endarterectomy, 409, 410
- randomized control trials, 272
- ACAS. *See* Asymptomatic Carotid Atherosclerosis Study
- ACST. *See* Asymptomatic Carotid Surgery Trial
- activated charcoal, 334
- acupuncture, 345
- acute cerebral ischemia
- brain development, 68
- diaschisis, 68
- hematoma, 69
- hydrocephalus, 69
- ischemic edema, 68
- CT imaging, 68
- ischemic penumbra, 67
- mechanisms, 65–67
- apoptosis, 67
- depolarization, 66
- excitotoxicity, 65–66
- inflammation, 66
- pathophysiology, 69
- recanalization, 67–68
- reperfusion, 67–68
- therapeutic time window, 67
- acute confusional state. *See* delirium
- acute intracerebral hemorrhage, treatment of
- cerebral cavernous malformations, 332–333
- dural arteriovenous fistulae, 333
- iatrogenic, 333–335
- anticoagulation therapy, 333–334
- aspirin therapy, 335
- with NOACs, 333–334
- thrombolytic therapy, 335
- warfarin therapy, 333–334
- lobar hemorrhage from
- amyloid angiopathy, 332
- Moyamoya syndrome, 333
- non-surgical approaches, 328–329
- blood pressure management, 328
- cerebrospinal fluid drainage, 329
- hyperventilation, 329
- osmotic agents, 329
- recombinant factor VIIa, 328–329
- pontine hemorrhages, 332
- surgical approaches, 329–332
- aspiration, 331–332
- cerebellar hemorrhage, 331
- decompressive craniectomy, 331
- supratentorial hemorrhage, 329–330
- acute posterior multifocal placoid pigment epitheliopathy, 93
- acute stroke. *See* major acute stroke
- acute treatment, of TIA and stroke
- aspirin, 285, 291–292
- clinical setting, 285–289
- EXPRESS study, 286–287, 288–289
- global service models, 285–286
- SOS-TIA study, 289, 290
- clopidogrel, 285, 291–292
- combination antiplatelet therapy, 291–292
- dipyridamole, 285
- early detection systems, 284
- management delays in, 282–285
- OXVASC, 283
- simvastatin, 291–292
- symptom recognition, 282–285
- public awareness of, 282–283
- through public behavior, 282–283
- recognition tools, 283–285
- ROSIER score, 283–285
- ticagrelor, 285
- African American populations
- hypertension, 21
- sickle cell disease, 94
- TIA and stroke, 11–12
- age
- carotid endarterectomy by, 400–401, 408
- cerebral venous thrombosis, 429
- as risk factor for TIA and stroke, 17
- AHA. *See* American Heart Association
- alcohol consumption, 25
- alteplase, 312–313
- Alzheimer's disease, 119–120
- dementia compared to, 459–460
- American Heart Association (AHA), 318–319
- American Stroke Association (ASA), 318–319
- amnesia. *See* transient global amnesia
- amphetamines, TIA and stroke, 25
- as cause, 99
- anemias, iron-deficiency, 94
- aneurysms
- extracranial arterial, 89
- intracranial arterial, 89
- unruptured, 449–451
- comorbid associations, 450
- interventions, 451
- rupture rates, 450
- angiitis
- primary, of central nervous system, 92
- sarcoid, 92

- angioendotheliosis. *See* malignant angioendotheliosis
- angiogram-negative SAH, 444–445
- angiography  
 catheter, 191–195  
 complications of, 192  
 historical development of, 191–192  
 noninvasive imaging compared to, 193–195  
 DSA, 444
- antibiotic therapy, infective endocarditis, 81–82
- anticoagulation treatment, 23, 360–365  
 apixaban, 334, 362–363  
 atrial fibrillation, 360, 361  
 CHA<sub>2</sub>DS<sub>2</sub>-VASc score, 364  
 dabigatran, 334, 362–363  
 edoxaban, 334, 362–363  
 endovascular therapy, 321  
 HAS-BLED score, 365  
 iatrogenic intracerebral hemorrhage, 333–334  
 NOACs, 361–362  
 rivaroxaban, 334, 362–363  
 SAME-TT<sub>2</sub>R<sub>2</sub> scores, 362  
 warfarin, 360–361, 362–363
- antiphospholipid syndrome, 90–91
- antiplatelet therapy, 357–359  
 acute treatment of TIA and stroke, 291–292  
 aspirin, 359–360  
 cerebral microbleeds, 117–118  
 clopidogrel, 359–360  
 dipyridamole, 359  
 endovascular therapy, 320–321  
 major trials, 357–358  
 mechanisms in, 359  
 warfarin, 360
- aortic and mitral valve calcification, 82
- aortic arch atheroma, 395
- aortic arch dissection, 87
- aphasia. *See* post-stroke aphasia
- apixaban, 334, 362–363
- apoptosis, acute cerebral ischemia, 67
- aripazine, 334
- ARR. *See* absolute risk reduction
- arterial disorders. *See* rare arterial disorders
- arterial dissection, 84–87  
 causes, 85–86  
 imaging for, 86  
 intracranial, 87  
 prognosis, 86–87
- arteriovenous malformations, 120–122
- ASA. *See* American Stroke Association
- Asians. *See* Japanese; South Asian populations
- aspiration, 331–332
- aspirin treatment  
 in acute treatment therapies, 285, 291–292  
 antiplatelet therapy, 359–360  
 carotid endarterectomy, 266  
 iatrogenic intracerebral hemorrhage, 335  
 during pregnancy, 96  
 in randomized control trials, 266, 268  
 vascular cognitive impairment, 480
- assessment of randomized control trials. *See* randomized control trials
- Asymptomatic Carotid Atherosclerosis Study (ACAS), 420, 424–425
- asymptomatic carotid stenosis, surgery for  
 benefits, 419–420, 422–423  
 identification, 419  
 individuals benefiting from, 425  
 patient selection, 421–425  
 gender factors, 424–425  
 range of stenosis as factor, 423  
 risks of, 421–422  
 subgroups benefiting from, 424–425
- Asymptomatic Carotid Surgery Trial (ACST), 420, 424–425
- atherosclerosis. *See* intracranial atherosclerosis
- atherothromboembolism, 71–77
- cholesterol embolization syndrome, 77  
 pathophysiology, 72, 73, 74  
 plaque activation, 75, 76–77, 78  
 racial prevalence rates, 71–72  
 stroke mechanisms, 74–76
- atrial fibrillation, 23  
 anticoagulation treatment, 360, 361  
 long-term prognosis, 261  
 medium-term prognosis, 261  
 non-valvular, prognosis of, 218–219  
 ARR, 218  
 prediction deficiencies, 218–219  
 scores, 218  
 NRAF, 261  
 paroxysmal, 23  
 persistent, 23
- atrial septal aneurysm, 83
- atrophic papulosis. *See* malignant atrophic papulosis
- AVERT. *See* A Very Early Rehabilitation Trial
- Behçet's disease, 91
- Bell, Benjamin, 374
- Biswanger's disease. *See* leukoaraiosis
- blindness. *See* transient monocular blindness
- blood gas tensions, 59
- blood lipids, 22–23
- blood pressure  
 acute intracerebral hemorrhage, 328  
 after major acute stroke, 301  
 TIA and stroke, 20–21  
 mortality rates, 21  
 prevention strategies, 363–366  
 by race, 20
- boundary zone infarcts, 146–147
- brain atrophy, 478–479
- brain development. *See* cerebral circulation; collateral blood supply; temporal lobe atrophy
- brain function, cerebral blood flow, 59

- brain imaging, for TIA and stroke. *See also* major acute stroke; vascular imaging
- arterial dissection, 86
- CAA, 119
- CT
- advantages and disadvantages, 161
  - technical aspects, 160
- for diagnosing, 166–171
- DWI, 166–171, 172, 174
- infarction, identification of, 163–164
- rates of, 163–164, 165, 168–169
- intracerebral hemorrhage, identification of, 163–164
- rates of hemorrhage, 163–164, 165
- microbleeds, 165–166
- MRI
- advantages and disadvantages, 161
  - dating infarctions, 168–169
  - technical aspects, 160
- noninvasive, 193–195
- non-neurovascular diagnoses, identification of, 159–163
- OXVASC, 161–163
- primary intracerebral hemorrhage, 115
- for prognostication, 166–171
- purpose, 159
- during recovery, 345–349
- DTI, 346
  - DWI, 345–346
  - fMRI, 347–349
  - MR spectroscopy, 346–347
  - MRI techniques, 345–346
- region of circulation, 173
- short-term prognosis with, 239–242
- stroke definition as result of, 3
- TIA definition as result of, 3
- Buerger's disease, 92
- CAA. *See* cerebral amyloid angiopathy
- CABG. *See* coronary artery bypass surgery
- CADASIL. *See* cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
- calcification. *See* aortic and mitral valve calcification
- cancer, TIA and stroke cause, 98
- candidate gene studies, 37
- cannabis, TIA and stroke, 25
- CARASIL. *See* cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy
- cardiac disorders, Mendelian stroke syndromes, 47
- cardiac investigations, 210–212
- cardiac myxomas, 83
- cardiac surgery, cardioembolism as result of, 84
- cardioembolism, 23, 80–84
- aortic and mitral valve calcification, 82
  - atrial septal aneurysm, 83
  - cardiac myxomas, 83
  - cardiac surgical complications, 84
  - causes, 81
  - coronary artery disease, 80
  - dilating cardiomyopathies, 83
  - infective endocarditis, 80–82
    - antibiotic therapy, 81–82
    - comorbidities, 82
  - instrumentation of coronary arteries and aorta, 84
  - marantic endocarditis, 82
  - mitral leaflet prolapse, 82
  - non-bacterial thrombotic endocarditis, 82
  - paradoxical embolism, 82–83
  - patent foramen ovale, 82–83
  - from prosthetic heart valves, 82
  - sinoatrial disease, 84
- cardiomyopathies, dilating, 83
- caroticocavernous fistula, 124
- carotid endarterectomy. *See also* carotid stenting
- ARR, 409, 410
  - aspirin treatment, 266
  - benefits, 380–382
  - ECST, 405, 412, 413, 414
  - eversion, 375
  - history of, 373–374
  - individuals benefiting from, 408–413
  - NASCET method, 403–407, 412
  - operation, 374–375
    - anesthesia, 376–377
    - shunting, 375
  - patch angioplasty, 375–376
  - patient selection for, 399–415
    - age factors, 400–401, 408
    - gender factors, 400–401, 408
    - with multiple potential causes of stroke, 413–415
    - near occlusions, 404, 407
    - presenting events, 400–401
    - range of stenosis as factor, 403–407
    - surgery risks, 399–403
  - post-surgical results, auditing and monitoring of, 403
  - predictive factors, 400
  - restenosis, 375–376
  - risks and complications, 377–380
    - cardiovascular, 379
    - cerebral hemorrhage, 379
    - cranial and peripheral nerve injuries, 379–380
    - death, 377
    - facial pain, 380
    - headache, 380
    - hyperfusion syndrome, 379
    - local wounds, 380
    - respiratory, 379
    - stroke from, 378, 381
    - perioperative, 378
    - postoperative, 378
    - subgroups benefiting from, 407–413
    - timing of, 402–403
- carotid stenosis. *See also* asymptomatic carotid stenosis
- stenting, 388
  - symptomatic, prognosis for, 260–261
- carotid stenting, 388–390, 391

- advantages and disadvantages, 389  
 complications, 389  
 extracranial, 390–391  
 MR angiography, 392  
 catheter angiography, 191–195  
 complications of, 192  
 historical development of, 191–192  
 noninvasive imaging compared to, 193–195  
 causes, TIA and stroke, 72. *See also* cardioembolism; inflammatory vascular disease; rare arterial disorders  
 aortic arch dissection, 87  
 arterial dissection, 84–87  
 causes, 85–86  
 imaging for, 86  
 intracranial, 87  
 prognosis, 86–87  
 atherothromboembolism, 71–77  
 cholesterol embolization syndrome, 77  
 pathophysiology, 72, 73, 74  
 plaque activation, 75, 76–77, 78  
 racial prevalence rates, 71–72  
 stroke mechanisms, 74–76  
 cancer, 98  
 chronic meningitis, 99  
 embolisms  
 fat, 101  
 fibrocartilaginous, 101  
 epidermal nevus syndrome, 101  
 Fabry disease, 100–101  
 homocystinuria, 101  
 hypercalcemia, 101  
 hypoglycemia, 101  
 hyponatremia, 101  
 inflammatory bowel disease, 99  
 large vessel disease, 71–77  
 leukoaraiosis, 79  
 comorbidities, 79  
 migraine, 97–98  
 ergotamines treatment, 98  
 estrogens and, 97  
 mechanisms, 97  
 triptans treatment, 98  
 miscellaneous, 95–101  
 mitochondrial cytopathy, 99–100  
 perioperative complications, 98  
 population-based studies, 73  
 pregnancy, 95–96  
 aspirin treatment, 96  
 clopidogrel therapy, 96  
 diagnostic and therapeutic approaches, 96  
 heparin therapy, 96  
 warfarin therapy, 96  
 rare, 95–101  
 recreational drug use, 99  
 small vessel disease, 78–79  
 snake bite, 101  
 Susac's syndrome, 101  
 transient focal neurological attacks, 127  
 trauma, 87  
 cavernous malformations, 123  
 CCMs, 332–333  
 cavernous sinus thrombosis, 431–432  
 CBF. *See* cerebral blood flow  
 CCMs. *See* cerebral cavernous malformations  
 Celiac disease, 99  
 cerebellar hemorrhage, 331  
 cerebellar stroke, 146  
 cerebral amyloid angiopathy (CAA), 119–120  
 Alzheimer's disease, 119–120  
 clinical presentation, 120  
 definite, 121  
 diagnosis, 120  
 familial, 48  
 imaging for, 119  
 modified Boston criteria for, 121  
 possible, 121  
 probable, 121  
 with supporting pathology, 121  
 cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 43–46, 460  
 cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), 46–47  
 cerebral blood flow (CBF), 185  
 cerebral blood flow, regulation of, 58–61  
 autoregulation, 59–60  
 blood gas tensions, 59  
 brain function, 59  
 hypertension, 61  
 perfusion pressure, 59–60  
 perfusion reserve, 60–61  
 impaired, 60–61  
 stroke, 61  
 cerebral cavernous malformations (CCMs), 332–333  
 cerebral circulation, anatomy of, 52–56  
 anterior arteries, 54, 55  
 cerebral, 54  
 choroidal, 54  
 communicating, 54  
 basilar artery, 56  
 carotid arteries  
 common, 52–53  
 external, 53  
 internal, 52–53  
 circle of Willis, 52, 54  
 middle cerebral artery, 54, 55  
 ophthalmic artery, 53  
 posterior arteries, 55  
 cerebral, 56  
 communicating, 54  
 vertebral artery, 54  
 cerebral ischemia. *See* acute cerebral ischemia  
 cerebral microbleeds, 115–118  
 antiplatelet therapy, 117–118  
 brain imaging, 165–166  
 locations, 117  
 vascular cognitive impairment, 476–478  
 warfarin therapy, 118  
 cerebral venous thrombosis  
 age of onset, 429  
 causes, 430  
 cavernous sinus thrombosis, 431–432  
 clinical features, 429–432  
 diagnosis  
 CT imaging, 430, 432–434  
 MRI imaging, 433–434  
 intracranial  
 hypertension, 435  
 symptoms, 431  
 treatment, 434–435  
 cerebrospinal fluid drainage, 329  
 CHA<sub>2</sub>DS<sub>2</sub>-VASc score, 364

- Chinese populations  
 Moyamoya syndrome, 88–89  
 Takayasu's arteritis, 92  
 TIA and stroke, 12
- cholesterol embolization syndrome, 77
- cholesterol levels, stroke risks and, 366–367  
 fibrates, 366  
 statins, 367
- chronic meningitis, 99
- chronic progressive subcortical encephalopathy. *See* leukoaraiosis
- Churg-Strauss syndrome, 91
- cigarette smoking  
 intracerebral hemorrhage, 21–22  
 SAH, 21–22  
 TIA and stroke, 21–22
- circle of Willis, 52, 54
- clarithromycin treatment, 26
- clinical features, of TIA and stroke, 128  
 cryptogenic drop attacks, 136  
 delirium, 135  
 epilepsy, 130–131  
 intracranial structural lesions, 131–133  
 tumors, 133
- isolated transient focal neurological disturbance of uncertain significance, 136
- mechanisms in, 129  
 low-flow, 129  
 subclavian steal, 129
- migraine with aura, 130
- mimics, 2, 130, 132, 133
- motor neuron disease, 135
- multiple sclerosis, 135
- myasthenia gravis, 135
- presyncope, 135
- psychogenic attacks, 136
- sensory systems  
 categorization of, 129  
 transient monocular blindness, 128, 130
- signs, 129
- symptoms, 127–129
- syncope, 135
- transient global amnesia, 133–134
- vascular distribution, 128  
 vestibular dysfunction, 134
- clofibrate, 269
- clopidogrel, 96  
 in acute treatment of TIA and stroke, 285, 291–292  
 antiplatelet therapy, 359–360
- cocaine, TIA and stroke, 25  
 as cause, 99
- COL4A1*-related intracerebral hemorrhage, 48
- collateral blood supply, to brain, 56–58  
 anastomoses  
 dural, 57  
 leptomeningeal, 57  
 parenchymal, 57
- Circle of Willis, 57
- leptomeningeal anastomoses, 57
- vertebral neck arteries, 57
- computed tomography (CT). *See also* brain imaging  
 advantages and disadvantages, 161  
 angiography, 197–198  
 CBF, 185  
 perfusion studies, 196–198
- cerebral venous thrombosis, 430, 432–434  
 major acute stroke, 176–183  
 advantages and disadvantages, 177  
 for hemorrhage, 176–178  
 ischemic changes, 178–183  
 perfusion techniques, 185–186  
 neurological deterioration, after major stroke, 250  
 SAH diagnosis, 439, 441–444, 447  
 technical aspects, 160
- congenital arterial anomalies, 88
- congenital carotid loops, 88
- Ehlers-Danlos syndrome, 88
- Marfan's syndrome, 88
- pseudoxanthoma elasticum, 88
- connective tissue disease, 47
- contraceptive use, risk factors for TIA and stroke, 20
- Cooper, Astley, 374
- coronary artery bypass surgery (CABG), 395, 426
- coronary artery disease, 80
- Coronary Drug Project, 269
- coronary heart disease, stroke and, 27  
 differences between, risk factors for, 17
- cranial and peripheral nerve injury, 379–380
- craniectomy. *See* decompressive craniectomy
- Creutzfeldt-Jacob disease, 140
- Crohn's colitis, 99
- cryptogenic drop attacks, 136
- CT. *See* computed tomography
- CT angiography, 197–198  
 CBF, 185  
 perfusion studies, 196–198
- dabigatran, 334, 362–363
- decompressive craniectomy, 331
- deep vein thrombosis (DVT), 297–298
- definite CAA, 121
- DEFUSE study. *See* Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution study
- dehydration, 303
- delayed ischemia, 448
- delirium, 135, 468–469  
 dementia compared to, 469
- dementia, 463–469  
 Alzheimer's disease compared to, 459–460  
 definition, 457  
 delirium compared to, 469  
 epidemiology, 456–457  
 post-stroke/post-event, 464–466, 468  
 pre-event/pre-stroke, 467  
 stroke-associated, 464, 465
- depolarization, acute cerebral ischemia, 66
- depression, 300  
 with vascular cognitive impairment, 481
- desmoteplase, 313
- Desmoteplase In Acute Ischemic Stroke (DIAS) trial, 186–187

- developmental venous anomalies, 122–123
- diabetes mellitus, 22
- diagnosing, for TIA and stroke, brain imaging, 166–171
- DIAS trial. *See* Desmoteplase In Acute Ischemic Stroke trial
- diaschisis, 68
- diet, TIA and stroke, 24  
 Mediterranean diet, 24  
 sodium intake, 24
- differential diagnosis, of stroke, 139  
 boundary zone infarcts, 146–147
- cerebellar stroke, 146
- chest pain, 152
- through clinical examination, 153–155  
 of arterial pulses, 154  
 cardiac, 155  
 of cervical bruits, 154–155  
 of eyes, 154  
 of nails, 155–156  
 neurological, 153–154  
 of skin, 155–156
- cranial nerves, 147
- Creutzfeldt-Jacob disease, 140
- encephalitis by fever, 140
- epileptic seizures, 152  
 with fever, 155
- gradual onset, 149
- headache, 147–148, 149–151
- hysteria, 140
- intracranial abscess, 140
- intracranial tumor, 140
- lacunar syndromes, 143–144  
 ataxic hemiparesis, 144  
 pure motor deficits, 144  
 pure sensory deficits, 144  
 sensorimotor deficits, 144
- malaise, 152
- from medical history, 149–153  
 familial, 153  
 injury, 152  
 precipitating factors, 149  
 previous strokes in, 153
- metabolic encephalopathy, 140
- movement disorders, 148
- multiple sclerosis, 140
- pathophysiological mechanisms, 148
- peripheral nerve or root lesion, 140
- post-seizure hemiparesis, 140
- recreational drug use, 152
- self-audible bruits, 153
- somatization, 140
- subdural hematoma, 140
- thalamic stroke, 145–146
- though lesion site determination, 140–147  
 partial anterior circulation syndrome, 141–142, 143  
 posterior circulation syndromes, 144–145  
 total anterior circulation syndrome, 141, 142
- TOAST classification, 148–149  
 subtypes, 148–149  
 vascular risk factors, 152  
 Wilson's disease, 140
- differential diagnosis, of TIA, 130
- diffused weighted imaging (DWI), 166–171, 172, 174
- major acute stroke, 183–185  
 pattern identification, 184  
 recovery after stroke, 345–346
- diffusion tensor imaging, 479
- diffusion tensor imaging (DTI), 346
- digital subtraction angiography (DSA), 444
- dilating cardiomyopathies, 83
- dipyridamole, 285  
 antiplatelet therapy, 359
- disability, after major stroke, 248
- disseminated intravascular coagulation, 95
- diurnal variation, TIA and stroke, 13
- Dos Santos, Cid, 374
- drug use, TIA and stroke, 25
- DSA. *See* digital subtraction angiography
- DTI. *See* diffusion tensor imaging
- duplex sonography, 195–196  
 disadvantages, 196  
 plaques, 196
- dural arteriovenous fistulae, 333
- DVT. *See* deep vein thrombosis
- DWI. *See* diffused weighted imaging
- dyslipidemias, hereditary, 47
- dysphagia, 303
- dysplasia, fibromuscular, 87–88
- Early Use of Existing Preventive Strategies for Stroke (EXPRESS) study, 286–287, 288–289
- ECST. *See* European Carotid Surgery Trialists' Collaborative Group
- edema  
 cytotoxic, 68  
 ischemic, 68  
 CT imaging, 68  
 peri-infarct, 250  
 vasogenic, 68
- edoxaban, 334, 362–363
- EGOS. *See* Erasmus GBS Outcome Score
- Ehlers-Danlos syndrome, 88
- embolism. *See also*  
 atherothromboembolism;  
 cardioembolism;  
 paradoxical embolism  
 fat, 101  
 fibrocartilaginous, 101
- embolization. *See* recurrent embolization
- encephalitis by fever, 140
- ENCHANTED study. *See* Enhanced Control of Hypertension and Thrombolysis Stroke study
- endocarditis. *See* infective endocarditis; marantic endocarditis; non-bacterial thrombotic endocarditis
- endovascular therapy, for acute ischemic stroke, 186–187, 314–324  
 AHA/ASA guidelines for, 318–319  
 anticoagulation therapy, 321  
 antiplatelet therapy, 320–321



- endovascular therapy (cont.)  
   hypothermia, 323  
   intra-arterial  
     thrombolysis, 314  
   mechanical thrombectomy,  
     314–320, 323–324  
     clinical trials, 314–320  
     Rankin Scale scores,  
       316, 317  
   in mobile stroke units,  
     323–324  
   neuroprotective  
     interventions, 322–323  
   surgical decompression for  
     malignant middle  
     cerebral artery  
     infarction, 321, 322  
   systems of care, 323–324  
   through telemedicine,  
     323–324  
 Enhanced Control of  
   Hypertension and  
   Thrombolysis Stroke  
   (ENCHANTED)  
   study, 311  
 epidermal nevus  
   syndrome, 101  
 epilepsy, 130–131  
 epileptic seizures, 152  
   after major stroke, 251  
   prognosis, recurrence after  
   single seizure, 219  
   effectiveness of, 219  
   prediction  
     deficiencies, 219  
     risk prediction, 219  
   scores, 219  
 EPITHET study. *See*  
   Echoplanar Imaging  
   Thrombolytic  
   Evaluation Trial study  
 Erasmus GBS Outcome Score  
   (EGOS), 220  
 ergotamines, 98  
 essential thrombocythemia, 94  
 estrogen  
   migraines and, 97  
   transdermal, 19–20  
 European Carotid Surgery  
   Trialists' Collaborative  
   Group (ECST), 405,  
   412, 413, 414  
 eversion endarterectomy, 375  
 excessive irradiation. *See*  
   irradiation  
 excitotoxicity, 65–66  
 exercise, TIA and stroke, 24  
 EXPRESS study. *See* Early Use  
   of Existing Preventive  
   Strategies for Stroke  
   study  
 extracranial arterial  
   aneurysms, 89  
 extracranial carotid stenting,  
   390–391  
 extracranial-to-intracranial  
   bypass surgery, 394–395  
 Fabry disease, 47,  
   100–101  
 facial pain, 380  
 familial CAA, 48. *See also*  
   cerebral amyloid  
   angiopathy  
 fat embolism, 101  
 fatigue, 345  
 fever  
   in differential diagnosis of  
   stroke, 155  
   encephalitis by fever,  
     140  
   after major acute stroke,  
     302–303  
 fibrates, 366  
 fibrocartilaginous  
   embolism, 101  
 fibromuscular dysplasia,  
   87–88  
 first-line investigations, 207  
 Fleming, David, 374  
 fluid imbalance, 299  
 functional magnetic resonance  
   imaging (fMRI),  
   347–349  
   vascular cognitive  
   impairment, 479  
 gastrointestinal bleeding, 300  
 GBD. *See* Global Burden of  
   Diseases, Injuries, and  
   Risk Factors Study  
 GBS. *See* Guillain-Barré  
   syndrome  
 gender. *See also* women  
   asymptomatic carotid  
   stenosis, 424–425  
   carotid endarterectomy and,  
   400–401, 408  
   risk factors for TIA and  
   stroke, 17–20  
 genetic risk factors, for TIA  
   and stroke, 20, 36. *See*  
   *also* Mendelian stroke  
   syndromes  
   for sporadic stroke, 35–43  
   candidate gene studies, 37  
   GWAS studies, 37–43  
   intermediate phenotype  
   studies, 43  
   ISGC study, 35–37  
   linkage studies, 37  
   NINDS study, 35–37  
   SiGN study, 35–37  
   variations of non-Mendelian  
   inheritance, 41–42, 48  
   intracerebral hemorrhage,  
   44–45  
 genome-wide association  
   studies (GWAS), 37–43  
 giant cell arteritis, 89–90  
 Global Burden of Diseases,  
   Injuries, and Risk  
   Factors Study  
   (GBD), 4–5  
 global stroke burden, 4–5  
   modifiable risk factors for  
   TIA and stroke, 20  
 glucose control, 367  
 gradient-echo imaging  
   (GRE), 176  
 Guillain-Barré syndrome  
   (GBS), prognosis of, 220  
   effectiveness of, 220  
   EGOS, 220  
   prediction deficiencies, 220  
   risk prediction, 220  
   scores, 220  
 GWAS. *See* genome-wide  
   association studies  
 HAS-BLED score, 365  
 HbA1c. *See* higher glycosylated  
   hemoglobin  
 headache, 147–148,  
   149–151, 380  
 Heart Protection Collaborative  
   Study Group, 22–23  
 hematocrit levels, 26  
   polycythemia, 94  
 hematological disorders, 93–95  
   disseminated intravascular  
   coagulation, 95  
   essential  
     thrombocythemia, 94  
   hemoglobinopathies, 94  
   iron-deficiency anemia, 94  
   leukemia, 93–94  
   lymphoma, 93–94

- malignant  
 angioendotheliosis, 93–94
- Mendelian stroke  
 syndromes, 47
- paraproteinemias, 95
- paroxysmal nocturnal  
 hemoglobinuria, 95
- polycythemia, 94
- sickle cell disease, 94
- thrombophilias, 93
- thrombotic  
 thrombocytopenic  
 purpura, 95
- hematoma  
 acute cerebral ischemia, 69
- intracerebral, 449
- subdural, 140
- hemoglobinopathies, 94
- hemorrhage. *See also*  
 intracerebral  
 hemorrhage;  
 subarachnoid  
 hemorrhage
- cerebellar, 331
- lobar, from amyloid  
 angiopathy, 332
- pontine, 332
- supratentorial, 329–330
- hemorrhagic transformation,  
 249–250
- hemostatic variables, 26
- heparin, during pregnancy, 96
- hereditary dyslipidemias, 47
- higher glycosylated  
 hemoglobin  
 (HbA1c), 22
- homocysteinemia, 26
- homocystinuria, 101
- hormone replacement therapy  
 risk factor for TIA and  
 stroke, 19–20
- transdermal estrogen, 19–20
- hormones. *See* estrogen
- hydrocephalus, 69, 448
- hypercalcemia, 101
- hyperfusion syndrome, 379
- hyperglycemia, 302
- hypertension  
 African Americans, 21
- cerebral blood flow  
 regulation, 61
- intracerebral hemorrhage,  
 118–119
- intracranial, 435
- TIA and stroke, 20–21
- by race, 21
- hypertonic saline, 329
- hyperventilation, 329
- hyperviscosity syndrome, 95
- hypoglycemia, 101
- hyponatremia, 101, 448
- hypotension, aortic arch  
 dissection, 87
- hypothermia, 323
- hypoxia, 302
- hysteria, 140
- iatrogenic intracerebral  
 hemorrhage, treatment  
 of, 333–335
- anticoagulation therapy,  
 333–334
- aspirin therapy, 335
- with NOACs, 333–334
- thrombolytic therapy, 335
- warfarin therapy, 333–334
- idarucizumab, 334
- imaging. *See* brain imaging
- impaired perfusion reserve,  
 60–61
- impaired swallowing. *See*  
 dysphagia
- infarction, boundary zone,  
 146–147
- infarction, infarcts and  
 brain imaging, identification  
 of, 163–164
- rates of infarction,  
 163–164, 165,  
 168–169
- CADASIL, 43–46
- CARASIL, 46–47
- major acute stroke compared  
 to, 176
- peri-infarct edema, 250
- surgical decompression for  
 malignant middle  
 cerebral artery  
 infarction, 321, 322
- vascular cognitive  
 impairment, 476–478
- infections, TIA and stroke, 26
- infective endocarditis, 80–82
- antibiotic therapy, 81–82
- comorbidities, 82
- inflammation  
 acute cerebral ischemia, 66
- TIA and stroke, 26
- inflammatory bowel disease, 99
- inflammatory vascular  
 diseases, 89–93
- acute posterior multifocal  
 placoid pigment  
 epitheliopathy, 93
- angiitis  
 primary, of central  
 nervous system, 92
- sarcoid, 92
- antiphospholipid syndrome,  
 90–91
- Behçet’s disease, 91
- Buerger’s disease, 92
- giant cell arteritis, 89–90
- malignant atrophic  
 papulosis, 92
- primary systemic  
 vasculitis, 91
- progressive systemic  
 sclerosis, 91
- relapsing polychondritis, 91
- rheumatoid disease, 91
- Sjögren’s syndrome, 91
- systemic lupus  
 erythematosus, 90
- Takayasu’s arteritis, 92
- innominate artery steal, 200–200
- instrumentation of coronary  
 arteries and aorta, 84
- insulin resistance, 22
- intermediate phenotype  
 studies, 43
- International Stroke Genetics  
 Consortium (ISGC),  
 35–37
- International Stroke Trial (IST-  
 3), 309–311
- intra-arterial thrombolysis, 314
- intracerebral hematoma, 449
- intracerebral hemorrhage. *See also*  
 acute intracerebral  
 hemorrhage, treatment  
 of; cerebral amyloid  
 angiopathy
- brain imaging, 163–164
- for primary intracerebral  
 hemorrhage, 115
- rates of hemorrhage,  
 163–164, 165
- from carotid  
 endarterectomy, 379
- cerebral microbleeds,  
 115–118
- antiplatelet therapy,  
 117–118
- locations, 117
- warfarin therapy, 118
- cigarette smoking, 21–22



- intracerebral (cont.)  
 classification of, 113  
*COL4A1*-related, 48  
 hypertension, 118–119  
 intracranial vascular malformations, 120–124  
 arteriovirus malformations, 120–122  
 caroticoavernous fistula, 124  
 cavernous malformations, 123  
 developmental venous anomalies, 122–123  
 telangiectasias, 123  
 long-term prognosis, 260  
 medium-term prognosis, 260  
 primary, 113–114  
 brain imaging, 176, 179, 183  
 causes of, 113, 114, 116  
 imaging of, 115  
 incidence rates, 113  
 primary intraventricular hemorrhage, 118  
 risk variations of non-Mendelian inheritance, 44–45  
 secondary preventions after, 368  
 subdural, 117, 118  
 intracranial abscess, 140  
 intracranial arterial aneurysms, 89  
 intracranial arterial dissection, 87  
 intracranial atherosclerosis, 392–394  
 intracranial hypertension, 435  
 intracranial structural lesions, 131–133  
 tumors, 133  
 intracranial tumor, 140  
 intracranial vascular malformations, 120–124  
 arteriovirus malformations, 120–122  
 caroticoavernous fistula, 124  
 cavernous malformations, 123  
 developmental venous anomalies, 122–123  
 telangiectasias, 123  
 intravenous thrombolysis, as treatment for acute ischemic stroke, 307–314  
 alteplase, 312–313  
 desmoteplase, 313  
 development timeline, 307–308  
 NOACs, 313–314  
 outcomes, 309, 310  
 randomized clinical trials, 308–309  
 ENCHANTED study, 311  
 IST-3, 309–311  
 Stroke Thrombolysis Trialists' Collaboration, 308–309  
 tenecteplase, 311  
 intraventricular hemorrhage.  
*See* primary intraventricular hemorrhage  
 iron-deficiency anemia, 94  
 irradiation, excessive, rare arterial disorders, 89  
 ischemic edema, 68  
 CT imaging, 68  
 ischemic penumbra, 67, 186–187  
 ISGC. *See* International Stroke Genetics Consortium  
 isolated transient focal neurological disturbance of uncertain significance, 136  
 IST-3. *See* International Stroke Trial  
 Japanese populations  
 Moyamoya syndrome, 88–89  
 Takayasu's arteritis, 92  
 Jervell syndrome, 47  
 lacunar syndromes, 143–144  
 ataxic hemiparesis, 144  
 pure motor deficits, 144  
 pure sensory deficits, 144  
 sensorimotor deficits, 144  
 Lange syndrome, 47  
 large vessel disease, 71–77  
 lateral medullary syndromes, 145  
 lesions. *See* intracranial structural lesions  
 leukemia, 93–94  
 leukoaraiosis, 79  
 comorbidities, 79  
 Life Long After Cerebral Ischemia (LILAC) study, 254–255, 259  
 linkage studies, 37  
 lobar hemorrhage from amyloid angiopathy, 332  
 locked-in syndrome, 145  
 long-term prognosis  
 LILAC study, 254–255, 259  
 risk prediction, 256–261  
 atrial fibrillation, 261  
 intracerebral hemorrhage, 260  
 symptomatic carotid stenosis, 260–261  
 vascular event predictors, 259–260  
 after stroke, 255–256  
 myocardial infarction risks, 256, 257  
 vascular death risks, 256  
 after TIA, 253–255  
 event rates, 255  
 myocardial infarction risks, 256, 257  
 vascular death risks, 256  
 low-flow mechanisms, with TIA, 129  
 lumbar puncture, for SAH diagnosis, 443  
 lymphoma, 93–94  
 macroglobulinemia, 95  
 magnetic resonance imaging (MRI). *See also* brain imaging  
 advantages and disadvantages, 161  
 angiography, 197, 199, 392  
 SAH diagnosis, 444  
 cerebral venous thrombosis, 433–434  
 dating infarctions, 168–169  
 fMRI, 347–349  
 vascular cognitive impairment, 479  
 major acute stroke, 176–183  
 advantages and disadvantages, 177  
 for hemorrhage, 176–178

- ischemic changes, 178–183
- multimodal, 479
- stroke recovery, 345–346
- technical aspects, 160
- magnetic resonance (MR) spectroscopy, 346–347
- major acute stroke, acute treatment. *See also* endovascular therapy; intravenous thrombolysis
- blood pressure management after, 301
- dehydration after, 303
- dysphagia after, 303
- early mobilization of, 303
- fever after, 302–303
- hyperglycemia after, 302
- hypoxia after, 302
- medical complications, 296
  - cardiac complications, 299
  - depression, 300
  - DVT, 297–298
  - fluid imbalance, 299
  - gastrointestinal bleeding, 300
  - mechanical issues, 299
  - pain, 300
  - pneumonia, 297
  - pressure sores, 298
  - urinary incontinence, 298
  - UTIs, 298
- non-neurological complications, 296–297
- nutrition in, 303
- routine monitoring, 297
- Stroke Unit Trialists Collaboration, 301
- stroke units, 301
  - core features, 301
- major acute stroke, brain imaging in
  - with CT, 176–183
    - advantages and disadvantages, 177
    - for hemorrhage, 176–178
    - ischemic changes, 178–183
    - perfusion techniques, 185–186
  - DIAS trial, 186–187
  - with DWI, 183–185
    - patterns, 184
  - endovascular therapy, 186–187
  - GRE, 176
- infarction compared to, 176
- ischemic penumbra, 186–187
- with MRI, 176–183
  - advantages and disadvantages, 177
  - for hemorrhage, 176–178
  - ischemic changes, 178–183
  - with perfusion-weighted imaging, 184–185
  - patterns, 184
- primary intracerebral hemorrhage, 115, 176, 179, 183
- thrombolysis, 186–187
- major acute stroke, short-term prognosis after
  - dependency, 248
  - mortality rates, 246–248
    - predictive factors, 247
  - neurological deterioration, 248–251
    - CT imaging, 250
    - epileptic seizures, 251
    - hemorrhagic transformation, 249–250
    - peri-infarct edema, 250
  - propagating thrombosis, 250
  - recurrent embolization, 251
  - systemic causes, 248, 249, 251
  - outcomes, by period of time, 246
- malaise, 152
- malignant angioendotheliosis, 93–94
- malignant atrophic papulosis, 92
- mannitol, 329
- Maori, TIA and stroke, 12
- marantic endocarditis, 82
- Marfan's syndrome, 88
- MCI. *See* mild cognitive impairment
- mechanical thrombectomy, 314–320, 323–324
  - clinical trials, 314–320
  - Rankin Scale scores, 316, 317
- medial medullary syndromes, 145
- Mediterranean diet, 24
- medium-term prognosis
  - risk prediction, 256–261
    - atrial fibrillation, 261
    - intracerebral hemorrhage, 260
    - prognostic models, 258
    - symptomatic carotid stenosis, 260–261
  - vascular event predictors, 259–260
    - after stroke, 255–256
    - myocardial infarction risks, 256, 257
    - vascular death risks, 256
  - after TIA, 253–255
    - event rates, 255
    - myocardial infarction risks, 256, 257
    - vascular death risks, 256
- memantine, 481
- Mendelian stroke syndromes, 38–40, 43–48
  - CADASIL, 43–46
  - CARASIL, 46–47
  - cardiac disorders, 47
  - COL4A1-related intracerebral hemorrhage, 48
  - connective tissue disease, 47
  - Fabry disease, 47
  - familial CAA, 48
  - hematological disorders, 47
  - hereditary dyslipidemias, 47
- meningitis. *See* chronic meningitis
- menopause, risk factor for TIA and stroke, 18–19
- metabolic encephalopathy, 140. *See also* delirium
- metabolic syndrome, 24
- microbleeds. *See* cerebral microbleeds
- migraine, 97–98
  - with aura, 130
  - ergotamines treatment, 98
  - estrogens and, 97
  - mechanisms, 97
  - triptans treatment, 98
- mild cognitive impairment (MCI), 457–458, 459
- mimics, TIA and stroke, 2
- minor stroke, short-term prognosis after, 2–3

- minor stroke (cont.)  
 clinical settings for,  
 advantages and  
 disadvantages, 235  
 early risk of stroke, 231–232  
 identification of high-risk  
 patients, 232–236  
 with imaging, 239–242  
 recurrence risks, by vascular  
 territory, 237–238, 239  
 simple risk scores, 232–236  
 ABCD scoring systems,  
 235–236, 237,  
 240–242  
 stroke-free survival  
 scores, 238  
 underlying pathology risks,  
 238–239
- mitochondrial cytopathy,  
 99–100
- mitral leaflet prolapse, 82
- mobile stroke units, 323–324
- modifiable risk factors, for TIA  
 and stroke, 19, 20–27  
 alcohol consumption, 25  
 anticoagulation  
 treatment, 23  
 atrial fibrillation, 23  
 types of, 23  
 blood lipids, 22–23  
 blood pressure, 20–21  
 mortality rates, 21  
 by race, 20  
 cardioembolism, 23  
 cigarette smoking, 21–22  
 clarithromycin treatment, 26  
 contraceptive use, 20  
 diabetes mellitus, 22  
 diet, 24  
 Mediterranean diet, 24  
 sodium intake, 24  
 exercise, 24  
 global stroke burden, 20  
 HbA1c, 22  
 hematocrit levels, 26  
 hemostatic variables, 26  
 homocysteinemia, 26  
 hypertension, 20–21  
 by race, 21  
 infections, 26  
 inflammation, 26  
 insulin resistance, 22  
 metabolic syndrome, 24  
 non-stroke vascular  
 disease, 27  
 obesity, 24
- obstructive sleep apnea, 25  
 recreational drug use, 25  
 renal disease, 25
- Modified Rankin Scale, stroke  
 recovery, 343
- Moniz, Egas, 373
- monogenetic stroke  
 syndromes. *See*  
 Mendelian stroke  
 syndromes
- motor neuron disease, 135
- movement disorders, 148
- Moyamoya syndrome,  
 88–89, 333
- MR spectroscopy. *See* magnetic  
 resonance spectroscopy
- MRI. *See* magnetic resonance  
 imaging
- MRI angiography, 197,  
 199  
 SAH diagnosis, 444  
 multimodal MRI, 479
- multiple myelomas, 95
- multiple sclerosis, 135,  
 140
- myasthenia gravis, 135
- myocardial infarctions, 379  
 long-term prognosis,  
 256, 257  
 medium-term prognosis,  
 256, 257
- NASCET method,  
 403–407, 412
- National Institute of  
 Neurological Disorders  
 and Stroke (NINDS)  
 study, 35–37
- National Institutes of Health  
 Stroke Scale (NIHSS), 3
- near occlusions, carotid  
 endarterectomy,  
 404, 407
- neuroprotective interventions,  
 322–323
- Nielsen syndrome, 47
- NIHSS. *See* National Institutes  
 of Health Stroke Scale
- NINDS study. *See* National  
 Institute of  
 Neurological Disorders  
 and Stroke study
- NINDS/AIREN criteria,  
 vascular cognitive  
 impairment,  
 458–459, 460
- NOACs. *See* non-vitamin  
 K antagonist oral  
 anticoagulants
- non-bacterial thrombotic  
 endocarditis, 82
- non-neurovascular diagnoses,  
 brain imaging for,  
 159–163
- non-radiological investigations  
 baseline non-imaging  
 tests, 208  
 cardiac, 210–212  
 first-line, 207  
 second-line, 207–209
- non-rheumatic atrial  
 fibrillation (NRAF),  
 261
- non-stroke vascular  
 disease, 27
- non-valvular atrial  
 fibrillation, prognosis  
 of, 218–219  
 ARR, 218  
 prediction deficiencies,  
 218–219  
 scores, 218
- non-vitamin K antagonist oral  
 anticoagulants  
 (NOACs), 313–314  
 anticoagulation treatment,  
 361–362  
 iatrogenic intracerebral  
 hemorrhage, 333–334
- Norwegian Vitamin Trial  
 (NORVIT), 26
- NRAF. *See* non-rheumatic  
 atrial fibrillation
- obesity, TIA and stroke, 24
- obstructive sleep apnea, 25
- occupational therapy,  
 343–344
- opiates, TIA and stroke, 99
- osmotic agents, 329
- Oxford Vascular Study  
 (OXVASC), 6, 19, 131  
 acute treatment of TIA and  
 stroke, 283  
 brain imaging, 161–163
- Pacific Islanders, TIA and  
 stroke, 12
- pain, after major acute  
 stroke, 300
- paradoxical embolism, 82–83
- paraproteinemias, 95

- paroxysmal atrial  
 fibrillation, 23
- paroxysmal nocturnal  
 hemoglobinuria, 95
- partial anterior circulation  
 syndrome, in diagnosis  
 of stroke, 141–142, 143
- patch angioplasty, in carotid  
 endarterectomy,  
 375–376
- patent foramen ovale, 82–83
- penumbra. *See* ischemic edema
- perfusion computed  
 tomography, 185–186
- perfusion pressure, 59–60
- perfusion reserve, 60–61  
 impaired, 60–61
- perfusion studies  
 vascular imaging  
 CT angiography, 196–198
- perfusion-weighted imaging,  
 major acute stroke,  
 184–185
- pattern identification, 184
- peri-infarct edema, 250
- perimesencephalic SAH, 444
- peripheral nerve or root  
 lesion, 140
- peripheral nerves. *See* cranial  
 and peripheral nerve  
 injury
- periventricular  
 leukoencephalopathy, 80.  
*See also* leukoaraiosis
- persistent atrial fibrillation, 23
- physiotherapy, 343
- Pilot Investigation of Stem Cells  
 in Stroke (PISCES), 345
- plaques, 196
- pneumonia, 297
- polyarteritis nodosa, 91
- polycythemia, 94
- pontine hemorrhages, 332
- pontine syndromes, 145
- possible CAA, 121
- posterior circulation syndromes  
 stroke diagnosis, 144–145  
 vascular imaging, 199–200  
 innominate artery steal,  
 199–200  
 subclavian steal, 199
- post-seizure hemiparesis, 140
- post-stroke aphasia, 349
- pregnancy, TIA and stroke  
 during, 95–96  
 aspirin treatment, 96
- clopidogrel therapy, 96
- diagnostic and therapeutic  
 approaches, 96
- heparin therapy, 96
- warfarin therapy, 96
- pressure sores, 298
- presyncope, 135
- primary angiitis of central  
 nervous system, 92
- primary intracerebral  
 hemorrhage, 113–114
- brain imaging, 115, 176,  
 179, 183
- causes of, 113, 114, 116
- incidence rates, 113
- primary intraventricular  
 hemorrhage, 118
- primary systemic vasculitis, 91
- probable CAA, 121
- with supporting  
 pathology, 121
- prognosis, of TIA and stroke.  
*See also* long-term  
 prognosis; major acute  
 stroke; minor stroke
- ARR, 213, 218
- GBS, 220
- effectiveness of, 220
- EGOS, 220
- prediction  
 deficiencies, 220
- risk prediction, 220
- scores, 220
- measurement of, 215–217  
 criteria for, 221
- models for, 214–215  
 clinical credibility  
 prerequisites, 215
- development of, 221–223
- five-year risk, 216–217
- long-term prognosis, 258
- medium-term  
 prognosis, 258
- risk assessment, 214
- updating of, 226
- validation of, 224–226
- non-valvular atrial  
 fibrillation, 218–219
- ARR, 218
- prediction deficiencies,  
 218–219
- scores, 218
- prediction studies, 213–214,  
 218
- levels of evidence, 227
- reporting, 226
- prognostic studies, 213
- recurrence after single  
 epileptic seizure, 219
- effectiveness of, 219
- prediction  
 deficiencies, 219
- risk prediction, 219
- scores, 219
- risk scores, 223, 224
- GBS, 220
- non-valvular atrial  
 fibrillation, 218
- recurrence after single  
 epileptic seizure, 219
- progressive systemic  
 sclerosis, 91
- propagating thrombosis, 250
- prosthetic heart valves,  
 cardioembolism  
 from, 82
- pseudoxanthoma elasticum, 88
- psychogenic attacks, 136
- race factors  
 atherothromboembolism,  
 71–72
- blood pressure, 20
- hypertension, 21
- TIA and stroke, 10–13
- black populations, 11–12
- Chinese populations, 12
- Maori and Pacific  
 Islanders, 12
- South Asian  
 populations, 12
- randomized control trials,  
 assessment of
- ARR, 272
- aspirin therapy, 266, 268
- AVERT, 341
- external validity of, 270–278
- adverse treatment  
 effects, 278
- control treatment  
 appropriateness,  
 275–276
- follow-up measures,  
 277–278
- intervention  
 appropriateness,  
 275–276
- management  
 appropriateness,  
 275–276
- outcome measures,  
 276–277

- randomized (cont.)  
 participant center  
 selection, 273  
 patient characteristics,  
 274–275  
 patient selection and  
 exclusion, 273–274  
 run-in periods, 274  
 trial setting, 270–273  
 internal validity of, 266–269  
 balanced treatment  
 groups, 267  
 intention-to-treat  
 analysis, 269  
 length of trial, 267  
 outcome assessment, 268  
 patient involvement, 269  
 performance methods,  
 266  
 sample sizes, 267  
 interventions, 265  
 intravenous thrombolysis,  
 308–309  
 ENCHANTED study, 311  
 IST-3, 309–311  
 Stroke Thrombolysis  
 Trialists' Collaboration,  
 308–309  
 SAMMPRIS, 392–393  
 treatment decisions as result  
 of, 278–279  
 VISSIT, 393–394  
 warfarin treatment, 278  
 Rankin Scale scores, 316, 317.  
*See also* Modified  
 Rankin Scale  
 rare arterial disorders, 87–89  
 congenital  
 arterial anomalies, 88  
 carotid loops, 88  
 excessive irradiation, 89  
 extracranial arterial  
 aneurysms, 89  
 fibromuscular dysplasia,  
 87–88  
 intracranial arterial  
 aneurysms, 89  
 Moyamoya syndrome, 88–89  
 Recognition of Stroke in the  
 Emergency Department  
 (ROSIER) score,  
 283–285  
 recombinant factor VIIa,  
 328–329  
 recovery, after stroke  
 AVERT, 341  
 brain imaging, 345–349  
 DTI, 346  
 DWI, 345–346  
 fMRI, 347–349  
 MR spectroscopy,  
 346–347  
 MRI techniques, 345–346  
 fatigue, 345  
 functional outcome  
 predictions, 339–340  
 interventions, 342–345  
 acupuncture, 345  
 occupational therapy,  
 343–344  
 physiotherapy, 343  
 secondary  
 consequences, 345  
 speech therapy, 344  
 stem cell therapy, 345  
 mechanisms of, 339  
 Modified Rankin Scale, 343  
 neglect impairment, 344  
 post-stroke aphasia, 349  
 through rehabilitation  
 assessment tools, 342  
 domain testing, 342  
 key components, 341–342  
 strategies for, 340–342  
 teams, 342–343  
 scope of, 339–340  
 selective serotonin receptor  
 inhibitors, 345  
 spasticity, 344–345  
 recreational drug use, TIA and  
 stroke, 25, 99. *See also*  
*specific drugs*  
 differential diagnosis, 152  
 recurrent embolization, 251  
 rehabilitation, stroke recovery  
 assessment tools, 342  
 domain testing, 342  
 key components, 341–342  
 strategies for, 340–342  
 teams for, 342–343  
 relapsing polychondritis, 91  
 renal disease, TIA and  
 stroke, 25  
 restenosis, 375–376  
 rheumatoid disease, 91  
 risk factors, for TIA and stroke.  
*See also* genetic risk  
 factors; modifiable risk  
 factors, for TIA and  
 stroke  
 abdominal aortic  
 aneurysms, 27  
 coronary heart disease, 27  
 differences between, 17  
 non-modifiable, 17–20  
 age, 17  
 gender, 17–20  
 genetics, 20  
 sex hormones, 17–20  
 risk prediction, with TIA and  
 stroke  
 epileptic seizures, recurrence  
 after single seizure, 219  
 GBS prognosis, 220  
 long-term prognosis,  
 256–260  
 risk scores, in TIA and stroke  
 prognosis, 223, 224  
 GBS, 220  
 non-valvular atrial  
 fibrillation, 218  
 recurrence after single  
 epileptic seizure, 219  
 for short-term prognosis,  
 232–236  
 ABCD scoring systems,  
 235–236, 237, 240–242  
 stroke-free survival  
 scores, 238  
 rivaroxaban, 334, 362–363  
 Romano Ward syndrome, 47  
 ROSIER score. *See* Recognition  
 of Stroke in the  
 Emergency Department  
 score  
 SAH. *See* subarachnoid  
 hemorrhage  
 SAME-TT<sub>2</sub>R<sub>2</sub> scores, 362  
 SAMMPRIS. *See* Stenting  
 Aggressive Medical  
 Management for  
 Preventing Recurrent  
 Stroke in Intracranial  
 Stenosis  
 sarcoid angiitis, 92  
 seasonal factors, for TIA and  
 stroke, 13  
 second-line investigations,  
 207–209  
 seizures. *See* epileptic seizures  
 selective serotonin receptor  
 inhibitors, 345  
 self-audible bruits, 153  
 sensory systems, TIA and  
 categorization of, 129  
 transient monocular  
 blindness, 128, 130

- sex hormones, risk factors for  
TIA and stroke, 17–20
- short-term prognosis. *See*  
major acute stroke;  
minor stroke
- sickle cell disease, 94
- SiGN study. *See* Stroke  
Genetics Network study
- simvastatin, 291–292
- sinoatrial disease, 84
- Sjögren's syndrome, 91
- small vessel disease, 78–79
- snake bite, 101
- social factors, for TIA and  
stroke, 13
- sodium intake, TIA and  
stroke, 24
- somatization, 140
- sonography. *See* duplex  
sonography;  
transcranial Doppler  
sonography
- SOS-TIA study, 289, 290
- South Asian populations  
Moyamoya syndrome, 88–89  
Takayasu's arteritis, 92  
TIA and stroke, 12
- SPARCL. *See* Stroke  
Prevention by  
Aggressive Reduction in  
Cholesterol Levels
- spasticity, after stroke, 344–345
- speech therapy, 344
- spinal SAH, 445
- spontaneous SAH. *See*  
subarachnoid  
hemorrhage
- sporadic stroke, genetic risk  
factors, 35–43  
candidate gene studies, 37  
GWAS studies, 37–43  
intermediate phenotype  
studies, 43  
ISGC study, 35–37  
linkage studies, 37  
NINDS study, 35–37  
SiGN study, 35–37
- statins, 367
- stem cell therapy, 345
- Stenting Aggressive Medical  
Management for  
Preventing Recurrent  
Stroke in Intracranial  
Stenosis (SAMMPRIS),  
392–393
- stroke. *See also* differential  
diagnosis, of stroke;  
major acute stroke;  
minor stroke; recovery;  
risk factors  
after carotid  
endarterectomy,  
378, 381  
perioperative stroke, 378  
postoperative stroke, 378  
causes, 4  
cerebellar, 146  
cerebral blood flow  
regulation, 61  
cholesterol levels, 366–367  
coronary heart disease, 27  
risk factors for, 17  
definitions, 1–4  
advantages, 3  
disadvantages, 3  
history, 2  
imaging-based, 3  
diurnal variation, 13  
epidemiology, 5  
global burden, 4–5  
incidence rates, 5, 6–10  
by age, 8, 11  
definitions, 10  
hospital-based studies, 7  
population-based studies, 7  
medium and long-term  
prognosis after,  
255–256  
myocardial infarction  
risks, 256, 257  
vascular death risks, 256  
mimics, 2  
mortality rates, 5–6  
NIHSS, 3  
OXVASC, 6, 9  
prevalence rates, 5, 6–10  
definitions, 10  
race factors, 10–13  
black populations, 11–12  
Chinese populations, 12  
Maori and Pacific  
Islanders, 12  
South Asian  
populations, 12  
seasonal factors, 13  
secondary medical issues, 4  
social factors, 13  
thalamic, 145–146  
TIA compared to, 1, 2–3  
time trends, 6–10
- Stroke Genetics Network  
(SiGN) study, 35–37
- Stroke Prevention by  
Aggressive Reduction in  
Cholesterol Levels  
(SPARCL), 22–23
- Stroke Thrombolysis Trialists'  
Collaboration, 308–309
- Stroke Unit Trialists  
Collaboration, 301
- stroke-free survival scores, 238
- Study of Vitamins to Prevent  
Stroke (VITATOPS), 26
- subarachnoid hemorrhage  
(SAH), 21–22  
angiogram-negative, 444–445  
causes, 438–439  
clinical features, 439–441  
World Federation of  
Neurological Surgeons'  
Scale, 441  
clinical presentation,  
443–444  
complications, 448–449  
delayed ischemia, 448  
hydrocephalus, 448  
hyponatremia, 448  
intracerebral  
hematoma, 449  
long-term, 449  
rebleeding risks, 446  
diagnosis, 441–445  
CT imaging, 439,  
441–444, 447  
differential, 442  
DSA, 444  
lumbar puncture, 443  
MRI angiography, 444  
epidemiology, 438  
perimesencephalic, 444  
spinal, 445  
treatment, 445–448  
endovascular, 446–448  
general measures, 445–446  
surgical, 446–448  
unruptured aneurysms,  
449–451  
comorbid  
associations, 450  
interventions, 451  
rupture rates, 450
- subclavian steal mechanisms,  
with TIA, 129
- subclavian steal syndrome,  
199, 394



- subcortical arteriosclerotic encephalopathy. *See* leukoaraiosis
- subdural hematoma, 140
- subdural intracerebral hemorrhage, 117, 118
- supratentorial hemorrhage, 329–330
- surgery. *See specific surgical procedures*
- surgical decompression for malignant middle cerebral artery infarction, 321, 322
- Susac's syndrome, 101
- susceptibility-weighted imaging (SWI), 176
- sympathomimetics, 25
- symptomatic carotid stenosis, prognosis for, 260–261
- syncope, 135
- systemic lupus erythematosus, 90
- systemic vasculitis. *See* primary systemic vasculitis
- Takayasu's arteritis, 92
- telangiectasias, 123
- telemedicine, 323–324
- temporal lobe atrophy, 478–479
- tenecteplase, 311
- thalamic stroke, 145–146
- thrombocytopenia. *See* essential thrombocytopenia
- thrombolysis, 186–187
- iatrogenic intracerebral hemorrhage, 335
- intra-arterial, 314
- thrombophilias, 93
- thrombosis. *See* propagating thrombosis
- thrombotic thrombocytopenic purpura, 95
- TIA. *See* transient ischemic attack
- ticagrelor, 285
- time trends, 6–10
- TOAST classification, in diagnosis of stroke, 148–149
- subtypes, 148–149
- top of the basilar syndrome, 145
- total anterior circulation syndrome, in diagnosis of stroke, 141, 142
- toxic confusional state. *See* delirium
- transcranial Doppler sonography, 200–201
- transdermal estrogen, 19–20
- transient focal neurological attacks, 127
- transient global amnesia, 133–134
- transient ischemic attack (TIA). *See also* causes; clinical features; risk factors
- definitions, 1–4
- advantages, 3
- disadvantages, 3
- history, 2
- imaging-based, 3
- differential diagnosis of, 130
- diurnal variation, 13
- epidemiology, 5
- global burden, 4–5
- incidence rates, 5, 6–10
- by age, 8, 11
- definitions, 10
- hospital-based studies, 7
- population-based studies, 7
- medium and long-term prognosis after, 253–255
- event rates, 255
- myocardial infarction risks, 256, 257
- vascular death risks, 256
- mimics, 2, 130, 132, 133
- mortality rates, 5–6
- OXVASC, 6, 9, 131
- prevalence rates, 5, 6–10
- definitions, 10
- race factors, 10–13
- black populations, 11–12
- Chinese populations, 12
- Maori and Pacific Islanders, 12
- South Asian populations, 12
- seasonal factors, 13
- social factors, 13
- stroke compared to, 1, 2
- minor, 2–3
- time trends, 6–10
- transient monocular blindness, 128, 130
- trauma, 87
- treatment therapies. *See also* acute treatment
- antibiotics, infective endocarditis, 81–82
- anticoagulation, for TIA and stroke, 23
- cerebral venous thrombosis, 434–435
- clarithromycin, 26
- infective endocarditis, 81–82
- occupational therapy, 343–344
- physiotherapy, 343
- speech therapy, 344
- stem cell therapy, 345
- triptans, 98
- tumors
- intracranial, 140
- intracranial structural lesions, 133
- type 2 diabetes, 367
- unruptured aneurysms, 449–451
- comorbid associations, 450
- interventions, 451
- rupture rates, 450
- urinary incontinence, 298
- urinary tract infections (UTIs), 298
- vascular cognitive impairment. *See also* dementia
- Alzheimer's disease, 462–463
- dementia compared to, 459–460
- brain atrophy, 478–479
- CADASIL, 460
- clinical features, 457–462
- definitions, 457–462
- delirium, 468–469
- dementia compared to, 469
- depression with, 481
- diffusion tensor imaging, 479
- epidemiology, 456–457
- fMRI, 479
- investigation of, 475–476
- routine tests, 476
- MCI, 457–458
- measurement scores, 461, 462
- microbleeds, 476–478
- multimodal MRI, 479

- NINDS/AIREN criteria, 458–459, 460  
 screening instruments, 460–462  
   measurement scores, 461, 462  
 silent infarcts, 476–478  
 stroke-associated, 463–469  
 subtypes, 458  
 temporal lobe atrophy, 478–479  
 treatments for, 480–481  
   with aspirin, 480  
   memantine, 481  
   primary interventions, 480  
   secondary interventions, 480  
 white matter disease, 476–478  
 vascular disease. *See* inflammatory vascular disease  
 vascular distribution, with TIA, 128  
 vascular imaging  
   catheter angiography, 191–195  
   complications of, 192  
   historical development of, 191–192  
   noninvasive imaging compared to, 193–195  
 CT angiography, 197–198  
   CBF, 185  
   perfusion studies, 196–198  
 duplex sonography, 195–196  
 disadvantages, 196  
   plaques, 196  
 MRI angiography, 197, 199  
 perfusion studies  
   CT angiography, 196–198  
   posterior circulation, 199–200  
   innominate artery steal, 200–200  
   subclavian steal, 199  
 transcranial Doppler sonography, 200–201  
 vascular malformations. *See* intracranial vascular malformations  
 venous drainage, anatomy of, 58  
 vertebrobasilar ischemia, 391  
 vertigo, 134. *See also* vestibular dysfunction  
 A Very Early Rehabilitation Trial (AVERT), 341  
 vestibular dysfunction, 134  
 VISP. *See* Vitamin Intervention for Stroke Prevention Study  
 VISSIT. *See* Vitesse Intracranial Stent Study for Ischemic Stroke Therapy  
 Vitamin Intervention for Stroke Prevention Study (VISP), 26  
 vitamin K antagonists. *See* warfarin  
 VITATOPS. *See* Study of Vitamins to Prevent Stroke  
 Vitesse Intracranial Stent Study for Ischemic Stroke Therapy (VISSIT), 393–394  
 warfarin, 23  
   anticoagulation treatment, 360–361, 362–363  
   antiplatelet therapy, 360  
   cerebral microbleeds, 118  
   iatrogenic intracerebral hemorrhage, 333–334  
   during pregnancy, 96  
   in randomized control trials, 278  
 Wegener's granulomatosis, 91  
 white matter disease, 476–478  
 Wilson's disease, 140  
 women  
   asymptomatic carotid stenosis, 424–425  
   carotid endarterectomy, 400–401, 408  
   risk factors for TIA and stroke, 17–20  
   contraceptive use, 20  
   hormonal therapy, 19–20  
   menopause, 18–19  
   transdermal estrogen, 19–20  
 World Federation of Neurological Surgeons' Scale, 441  
 wounds, local, 380  
 Wyeth, John, 374